Delia Bishara BPharm, MSc, MCMHP, Eromona Whiskey BPharm, MCMHP, David Taylor MSc, PhD MRPharmS
{"title":"Asenapine: novel antipsychotic for treatment of bipolar I disorder","authors":"Delia Bishara BPharm, MSc, MCMHP, Eromona Whiskey BPharm, MCMHP, David Taylor MSc, PhD MRPharmS","doi":"10.1002/fps.84","DOIUrl":null,"url":null,"abstract":"<p><b>Asenapine is a new antipsychotic agent with activity for multiple receptors. It is administered sublingually for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. In this Drug profile the authors review the pharmacodynamic and pharmacokinetic properties of asenapine, and discuss its efficacy in bipolar I disorder and its likely positioning in clinical practice.</b> Copyright © 2011 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 4","pages":"5-9"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.84","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.84","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Asenapine is a new antipsychotic agent with activity for multiple receptors. It is administered sublingually for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. In this Drug profile the authors review the pharmacodynamic and pharmacokinetic properties of asenapine, and discuss its efficacy in bipolar I disorder and its likely positioning in clinical practice. Copyright © 2011 John Wiley & Sons, Ltd.
阿塞那平:治疗双相I型障碍的新型抗精神病药
阿塞那平是一种新的抗精神病药物，具有多受体活性。它是舌下给药，用于治疗成人双相I型障碍相关的中度至重度躁狂发作。在这篇药物简介中，作者回顾了阿塞那平的药效学和药代动力学特性，并讨论了其在双相I型障碍中的疗效及其在临床实践中的可能定位。版权所有©2011 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
